Video

VIDEO: ASCO data highlights promise of bispecific antibodies

CHICAGO — Venkateshwar “Venkat” Reddy, PhD, vice president and global head of translational science for Glenmark Pharmaceuticals, spoke with HemOnc Today at ASCO Annual Meeting about the company’s bispecific T-cell engager platform.

At ASCO, researchers presented preclinical and translational data on GBR 1302 (Glenmark), a HER-2 and CD3 bispecific antibody under investigation for treatment of a variety of HER-2-positive cancers.

“If you look at solid tumors, where some [chimeric antigen receptor T-cell therapies and checkpoint inhibitors] have not been effective, I think bispecific molecules are showing the promise where you can infiltrate these immune cells into the solid tumors and actually have an impact,” Reddy told HemOnc Today.

Investigators also presented a trial-in-progress poster about GBR 1342 (Glenmark), a CD38 and CD3 bispecific antibody under investigation for treatment of refractory multiple myeloma.

CHICAGO — Venkateshwar “Venkat” Reddy, PhD, vice president and global head of translational science for Glenmark Pharmaceuticals, spoke with HemOnc Today at ASCO Annual Meeting about the company’s bispecific T-cell engager platform.

At ASCO, researchers presented preclinical and translational data on GBR 1302 (Glenmark), a HER-2 and CD3 bispecific antibody under investigation for treatment of a variety of HER-2-positive cancers.

“If you look at solid tumors, where some [chimeric antigen receptor T-cell therapies and checkpoint inhibitors] have not been effective, I think bispecific molecules are showing the promise where you can infiltrate these immune cells into the solid tumors and actually have an impact,” Reddy told HemOnc Today.

Investigators also presented a trial-in-progress poster about GBR 1342 (Glenmark), a CD38 and CD3 bispecific antibody under investigation for treatment of refractory multiple myeloma.

    See more from ASCO Annual Meeting